Key points are not available for this paper at this time.
The GLP-1R agonist exenatide can inhibit the activation state of platelets in patients with T2DM and inhibit thrombosis, which is beneficial to reduce the risk of cardiovascular events.
Zhang et al. (Thu,) studied this question.